RT @Stiddyo: #OP0233 In SELECT-PsA1 & 2 analyses for PsA with axial involvement: 31% / 34% of the studies populatio
Tweet Content
#OP0233 In SELECT-PsA1 & 2 analyses for PsA with axial involvement: 31% / 34% of the studies population:
> Improvement of axial symptoms on upadacitinib across several outcomes compared to PLC!
> 1new onset of uveitis on upadacitinib
#EULAR2021
@RheumNow https://t.co/9YK1OYEorq
Show on Archive Page
On
Display in Search Results
On
PDQ
Off